Brian Kobilka’s lab at Stanford is not a place of spectacle. There are no giant particle accelerators or robotic arms dancing through the air. Instead, there are tubes, screens, quietly humming machines, and at the center of it all, a man whose work has illuminated one of the most important molecular communication systems in the human body.
Kobilka didn’t set out to become a molecular biologist. He trained as a physician, and it was only later, while working in Robert Lefkowitz’s lab at Duke, that he found himself pulled into the intricate puzzle of G-protein-coupled receptors (GPCRs). These receptors sit on the surface of nearly every cell in the body, receiving signals, from hormones, neurotransmitters, even light, and translating them into cellular action. They’re the gateway through which the body listens and responds to its environment. They’re also the target of roughly a third of all modern medicines.
But in the 1980s, GPCRs were a black box. Kobilka was the one who helped pry it open.
He was the first to clone the gene for the beta-2 adrenergic receptor, a feat that required more than just technical skill. It required tenacity, a tolerance for failure, and the kind of stubborn optimism that keeps a person working late into the night long after others would’ve given up. Decades later, he would win the Nobel Prize in Chemistry, shared with Lefkowitz, for work that revealed the 3D structure of these receptors and how they function at the atomic level.
What’s striking about Kobilka is how unassuming he is. He doesn’t speak in grand pronouncements. He listens. He thinks before he talks. And when he does talk, he often downplays his role, crediting his collaborators, his students, and the field itself for its collective progress.
In person, he’s calm and deliberate, with the air of someone who’s spent a lifetime walking narrow paths between biology, chemistry, and physics. The lab behind him, filled with chromatography systems and delicate instrumentation, looks less like a cathedral of science and more like a watchmaker’s bench, an apt metaphor, really, for the kind of precision work that defines his career.
Beyond the bench, Kobilka is also a builder of teams. He and his wife, Dr. Tong Sun Kobilka, run the lab together, a partnership that has spanned decades of discovery. Many of their former trainees now lead labs of their own. The scientific lineage continues.
There’s something quietly radical in what Kobilka has done: he’s helped transform a once-intractable mystery, the invisible chatter between cells, into something we can see, understand, and even manipulate. His work has implications for everything from heart disease to mental health, from vision loss to cancer. Yet he remains focused not on the accolades but on the unanswered questions.
I photographed him in 2024 at his lab at Stanford. He stood in front of the machinery like it was an old friend, arms crossed, expression thoughtful, surrounded by the elegant tangle of tubes and wires that translate molecular whispers into data. The light came in softly through a side window. It felt quiet in the room. Focused. Like the man himself.
